Particle.news
Download on the App Store
3 ARTICLES
·
last mo.

AstraZeneca Pledges $50 Billion to U.S. Production and Research by 2030

Tariff threats from President Trump prompted the announcement in Washington under the shadow of a Commerce Department investigation.

Image
Image
Vor dem Hintergrund drohender US-Zölle hat der britische Pharmakonzern Astrazeneca angekündigt, 50 Milliarden Dollar (rund 42,8 Milliarden Euro) in den USA zu investieren.

Overview

  • The $50 billion commitment supplements a prior $3.5 billion U.S. pledge announced in late 2024, bringing total planned American investment to $53.5 billion.
  • CEO Pascal Soriot unveiled the plan in Washington alongside Virginia Governor Glenn Youngkin, projecting tens of thousands of new jobs.
  • The move addresses President Trump’s warnings of tariffs on imported pharmaceuticals and follows a Commerce Department investigation into drug imports.
  • AstraZeneca currently employs around 18,000 people in the U.S. and aims for half of its $80 billion revenue target by 2030 to come from the American market.
  • After canceling a €520 million U.K. vaccine plant earlier this year and weighing a potential listing shift from London to New York, AstraZeneca is focusing capital deployment in the U.S.